GYPC and infection: Lacidipine, which is a VGCC inhibitor, has been demonstrated to inhibit LASVpv and GTOVpv infections, as well as GPC-mediated membrane fusion, by targeting LASV T40 (in the ectodomain of SSP), GTOV V36 (in the ectodomain of SSP), and V436 (in TM domain of GP2; Wang et al., 2018).